Hester Biosciences Q4 Profit Surges 1,130% to ₹160M; ₹11 Dividend Recommended

Market snapshot: Hester Biosciences Limited has reported a massive 1,130% surge in consolidated net profit for Q4 FY26, reaching ₹160 million compared to ₹13 million in the previous year. The performance reflects strong operating leverage as the company’s poultry healthcare division capitalizes on expanded distribution and new vaccine launches.

Data Snapshot

• Consolidated Net Profit: ₹160M (vs ₹13M YoY)
• Standalone Net Profit: ₹106.6M (up 174% YoY)
• Dividend Recommendation: ₹11 per share (110% of face value)
• Consolidated Revenue: ₹841.05M (up 22% YoY)

What's Changed

• Net profit margins expanded dramatically from approx 1.6% to 19% on a consolidated basis due to high-margin vaccine sales and low base effect.
• Operational capacity in India doubled to 13.90 billion doses following the commercialization of the Kadi facility in December 2025.
• Dividend payout increased significantly to ₹11, signaling management confidence in cash flow sustainability from the new capacity.

Key Takeaways

• Poultry division remains the primary growth engine with 32% division-level growth.
• Animal Healthcare segment recovery expected to continue as government PPR orders materialize in FY27.
• Substantial improvement in consolidated EBITDA margins reaching 25%.

SAHI Perspective

The Q4 results validate Hester's transition from a capacity-constrained player to a volume-driven animal health major. The 1,130% profit jump is not merely a base effect but reflects the synchronization of India's capacity expansion with global vaccine demand. Investors should note the high dividend payout as a sign of matured cash-flow generation.

Market Implications

The sharp earnings beat is likely to act as a re-rating catalyst for the stock, which has been underperforming the broader index. The expansion into African markets via the Tanzania plant and WHO pre-qualification efforts for PPR vaccines position the company for a higher export revenue share in FY27.

Trading Signals

Market Bias: Bullish

1,130% YoY profit surge and 25% EBITDA margins signal a structural turnaround in profitability and operational efficiency.

Overweight: Animal Healthcare, Biotechnology, Poultry Vaccines

Trigger Factors:

• Execution of international PPR vaccine orders
• Utilization levels at the newly expanded 13.9 billion dose facility
• Tanzania plant contribution to consolidated margins

Time Horizon: Medium-term (3-12 months)

Industry Context

The animal healthcare industry in India is shifting toward preventative vaccination, supported by government initiatives like the National Animal Disease Control Programme. Hester occupies a dominant position as the largest manufacturer of PPR and Goat Pox vaccines in India.

Key Risks to Watch

• Regulatory delays in WHO pre-qualification for export vaccines
• Dependency on government institutional orders for the ruminant segment
• Raw material cost volatility affecting the specialty nutrition portfolio

Recent Developments

Hester commercialized its ₹63 crore India plant expansion in December 2025, doubling its dose capacity. The company also recently secured marketing licenses for the H9N2 Avian Influenza vaccine, strengthening its poultry portfolio. In May 2026, the company held multiple analyst meets to discuss the first formal FY27 guidance.

Closing Insight

Hester Biosciences has demonstrated significant financial resilience. With a de-leveraged balance sheet and a massive capacity runway, the company is well-positioned to capitalize on the increasing global focus on the 'One Health' narrative.

FAQs

What led to the 1,130% jump in net profit for Q4?

The surge was driven by a low base in the previous year, strong growth in the high-margin poultry healthcare division, and improved operating leverage from the newly expanded manufacturing capacity in India.

How does the India plant expansion impact future growth?

The expansion from 6.25 billion to 13.90 billion doses, commercialized in late 2025, allows Hester to fulfill massive domestic and export orders for vaccines like PPR and LSD without capacity constraints, potentially boosting margins further.

Is the ₹11 per share dividend sustainable?

With consolidated profit jumping to ₹160M and standalone operations generating healthy cash flows (CFO/PAT at 1.15), the ₹11 dividend reflects strong internal accruals and confidence in the FY27 outlook.

High Performance Trading with SAHI.